Alzheimers

Post Dates Subject to Change

 

Alzheimers: Non-amyloid targets in drug development?
(Post Date: 4/2/14)

What non-amyloid targets should be pursued for Alzheimer's disease therapies? We put the question to three well-known researchers in the field: Bradley Hyman, MD, PhD, of Massachusetts General Hospital in Boston; John Trojanowski, MD, PhD, of the University of Pennsylvania in Philadelphia; and Richard J. Caselli, MD, of the Mayo Clinic in Scottsdale, Ariz. Their answers ranged from tau protein pathologies to apolipoprotein E to general neuroprotection.

Alzheimers: Where do biomarkers fit in diagnosis?
(Post Date: 4/1/14)

Alzheimers: Initial triggers?
(Post Date: 4/3/14)

Alzheimers: FDA approval of dementia drug based on biomarkers?
(Post Date: 4/4/14)